Regeneron Pharmaceuticals: Q1 Earnings Insights


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


 

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) decreased 0.1% in pre-market trading after the company reported Q1 results.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Quarterly Results

Earnings per share rose 49.85% over the past year to $9.89, which beat the estimate of $9.03.

Revenue of $2,529,000,000 rose by 38.35% from the same period last year, which missed the estimate of $2,560,000,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Regeneron Pharmaceuticals hasn't issued any revenue guidance for the time being.


FREE REPORT: How To Learn Options Trading Fast

In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, ​a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.


How To Listen To The Conference Call

Date: May 06, 2021

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/9dtjbq5f

Technicals

52-week high: $664.64

Company's 52-week low was at $441.00

Price action over last quarter: down 2.61%

Company Overview

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: EarningsNewsBZI-Recaps